Literature DB >> 26026601

Immunotherapy Applied to Neuropsychiatric Disorders: a New Perspective of Treatment.

Pedro Luis Prior1.   

Abstract

Manipulation of the immunological system has lead to groundbreaking discoveries that have had deep impact in demographic and health worldwide. Newer research has made it clear that immunological treatment of neurological and neuropsychiatric diseases may present itself as a viable solution to many ailments. In this mini-review, results of immunotherapeutic studies are presented, indicating that this field may be important in elucidating the etiology of many neurological conditions, and presenting a therapeutic alternative to current treatments.

Entities:  

Mesh:

Year:  2015        PMID: 26026601     DOI: 10.1007/s12031-015-0587-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  26 in total

1.  Immune to addiction: the ethical dimensions of vaccines against substance abuse.

Authors:  Michael J Young; Dominic A Sisti; Hila Rimon-Greenspan; Jason L Schwartz; Arthur L Caplan
Journal:  Nat Immunol       Date:  2012-05-18       Impact factor: 25.606

Review 2.  Myasthenia gravis: newer therapies offer sustained improvement.

Authors:  Yuebing Li; Yeeshu Arora; Kerry Levin
Journal:  Cleve Clin J Med       Date:  2013-11       Impact factor: 2.321

3.  Clearing the way for tau immunotherapy in Alzheimer's disease.

Authors:  Abigail Herrmann; Tara Spires-Jones
Journal:  J Neurochem       Date:  2014-08-23       Impact factor: 5.372

Review 4.  Vaccine adjuvants--understanding molecular mechanisms to improve vaccines.

Authors:  Adrian Egli; Deanna Santer; Khaled Barakat; Martin Zand; Aviad Levin; Madeleine Vollmer; Maja Weisser; Nina Khanna; Deepali Kumar; Lorne Tyrrell; Michael Houghton; Manuel Battegay; Daire O'Shea
Journal:  Swiss Med Wkly       Date:  2014-05-20       Impact factor: 2.193

5.  Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Authors:  Margaret M Racke; Laura I Boone; Deena L Hepburn; Maia Parsadainian; Matthew T Bryan; Daniel K Ness; Kathy S Piroozi; William H Jordan; Donna D Brown; Wherly P Hoffman; David M Holtzman; Kelly R Bales; Bruce D Gitter; Patrick C May; Steven M Paul; Ronald B DeMattos
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

6.  AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior.

Authors:  Jonathan B Rosenberg; Martin J Hicks; Bishnu P De; Odelya Pagovich; Esther Frenk; Kim D Janda; Sunmee Wee; George F Koob; Neil R Hackett; Stephen M Kaminsky; Stefan Worgall; Nicole Tignor; Jason G Mezey; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2012-05       Impact factor: 5.695

7.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

Review 8.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20

Review 9.  Vaccines against stimulants: cocaine and MA.

Authors:  Thomas Kosten; Coreen Domingo; Frank Orson; Berma Kinsey
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 10.  Experimental treatments for cocaine toxicity: a difficult transition to the bedside.

Authors:  Nicholas J Connors; Robert S Hoffman
Journal:  J Pharmacol Exp Ther       Date:  2013-08-26       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.